Oncotelic Therapeutics, Inc.
OTLC
$0.04
$0.001.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7,010.70% | 510.83% | -31.78% | -39.53% | -68.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7,292.38% | 507.67% | -31.68% | -39.53% | -72.25% |
| Operating Income | -7,292.38% | -507.67% | 31.68% | 39.53% | 72.25% |
| Income Before Tax | 55,385.42% | 66.95% | 175.63% | 23.34% | 17.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38,341.88% | 66.95% | 175.63% | 23.34% | 17.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.80% | -0.30% | -1.32% | -1.50% | -2.90% |
| Net Income | 41,762.19% | 68.30% | 232.46% | 26.91% | 18.36% |
| EBIT | -7,292.38% | -507.67% | 31.68% | 39.53% | 72.25% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 37,926.67% | 69.14% | 240.00% | 30.00% | 28.57% |
| Normalized Basic EPS | -244.44% | -1,400.00% | 266.67% | 0.00% | -12.50% |
| EPS Diluted | 37,926.67% | 69.14% | 220.00% | 30.00% | 28.57% |
| Normalized Diluted EPS | -244.44% | -1,400.00% | 233.33% | 0.00% | -12.50% |
| Average Basic Shares Outstanding | 8.33% | 4.70% | 1.67% | 2.01% | 16.18% |
| Average Diluted Shares Outstanding | 8.33% | 4.70% | 12.75% | 2.01% | 16.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |